{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-010507","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.542239+00:00","generated_at":"2026-05-17T19:31:47.320456+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Voyager Q2 net loss widens to $33.4M; cash runway extended into 2028","bullets":["Net loss $33.4M in Q2 2025 vs $10.1M in Q2 2024; collaboration revenue fell to $5.2M from $29.6M.","Cash and marketable securities $262M; runway extended into 2028, enabling multiple clinical data readouts.","Added wholly-owned APOE program to Alzheimer's pipeline, fourth asset in franchise; tau PET data for VY7523 expected H2 2026.","Neurocrine-partnered FA and GBA1 gene therapy programs expected to enter clinical trials in 2026 after IND submissions in 2025.","Potential for $2.6B in development milestone payments from 11 partnered programs, including up to $35M from GBA and FA programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-010507","json":"https://secwatch.observer/filing/0001558370-25-010507.json","markdown":"https://secwatch.observer/filing/0001558370-25-010507.md","text":"https://secwatch.observer/filing/0001558370-25-010507.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000155837025010507/0001558370-25-010507-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000155837025010507/vygr-20250806x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:31:47.320456+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}